CONTEXT: Biomarkers that predict musculoskeletal response to anabolic therapies should expedite drug development. During collagen synthesis in soft lean tissue, N-terminal propeptide of type III procollagen (P3NP) is released into circulation. We investigated P3NP as a biomarker of lean body mass (LBM) and muscle strength gains in response to testosterone and GH. DESIGN: Community-dwelling older men received GnRH agonist plus 5 or 10 g testosterone gel plus 0, 3, or 5 microg recombinant human GH daily. P3NP levels were measured at baseline and wk 4, 8, 12, and 16. LBM and appendicular skeletal muscle mass (ASM) were measured by dual-energy x-ray absorptiometry. RESULTS: One hundred twelve men completed treatment; 106 underwent serum P3NP measurements. P3NP levels were higher at wk 4 than baseline (6.61 +/- 2.14 vs. 4.51 +/- 1.05, P < 0.0001) and reached plateau by wk 4 in men receiving testosterone alone. However, wk 8 P3NP levels were higher than wk 4 levels in men receiving testosterone plus recombinant human GH. Increases in P3NP from baseline to wk 4 and 16 were significantly associated with gains in LBM (r = 0.26, P = 0.007; r = 0.53, P < 0.001) and ASM (r = 0.17, P = 0.07; r = 0.40, P < 0.0001). Importantly, for participants receiving only testosterone, P3NP increases at wk 4 and 16 were related to muscle strength gains (r = 0.20, P = 0.056 and r = 0.36, P = 0.04). In stepwise regression, change in P3NP explained 28 and 30% of the change in ASM and LBM, respectively, whereas change in testosterone but not IGF-I and age provided only small improvements in the models. CONCLUSION: Early changes in serum P3NP levels are associated with subsequent changes in LBM and ASM during testosterone and GH administration. Serum P3NP may be a useful early predictive biomarker of anabolic response to GH and testosterone.
CONTEXT: Biomarkers that predict musculoskeletal response to anabolic therapies should expedite drug development. During collagen synthesis in soft lean tissue, N-terminal propeptide of type III procollagen (P3NP) is released into circulation. We investigated P3NP as a biomarker of lean body mass (LBM) and muscle strength gains in response to testosterone and GH. DESIGN: Community-dwelling older men received GnRH agonist plus 5 or 10 g testosterone gel plus 0, 3, or 5 microg recombinant human GH daily. P3NP levels were measured at baseline and wk 4, 8, 12, and 16. LBM and appendicular skeletal muscle mass (ASM) were measured by dual-energy x-ray absorptiometry. RESULTS: One hundred twelve men completed treatment; 106 underwent serum P3NP measurements. P3NP levels were higher at wk 4 than baseline (6.61 +/- 2.14 vs. 4.51 +/- 1.05, P < 0.0001) and reached plateau by wk 4 in men receiving testosterone alone. However, wk 8 P3NP levels were higher than wk 4 levels in men receiving testosterone plus recombinant human GH. Increases in P3NP from baseline to wk 4 and 16 were significantly associated with gains in LBM (r = 0.26, P = 0.007; r = 0.53, P < 0.001) and ASM (r = 0.17, P = 0.07; r = 0.40, P < 0.0001). Importantly, for participants receiving only testosterone, P3NP increases at wk 4 and 16 were related to muscle strength gains (r = 0.20, P = 0.056 and r = 0.36, P = 0.04). In stepwise regression, change in P3NP explained 28 and 30% of the change in ASM and LBM, respectively, whereas change in testosterone but not IGF-I and age provided only small improvements in the models. CONCLUSION: Early changes in serum P3NP levels are associated with subsequent changes in LBM and ASM during testosterone and GH administration. Serum P3NP may be a useful early predictive biomarker of anabolic response to GH and testosterone.
Authors: J D Wallace; R C Cuneo; P A Lundberg; T Rosén; J O Jørgensen; S Longobardi; N Keay; L Sacca; J S Christiansen; B A Bengtsson; P H Sönksen Journal: J Clin Endocrinol Metab Date: 2000-01 Impact factor: 5.958
Authors: R S Swerdloff; C Wang; G Cunningham; A Dobs; A Iranmanesh; A M Matsumoto; P J Snyder; T Weber; J Longstreth; N Berman Journal: J Clin Endocrinol Metab Date: 2000-12 Impact factor: 5.958
Authors: Marc R Blackman; John D Sorkin; Thomas Münzer; Michele F Bellantoni; Jan Busby-Whitehead; Thomas E Stevens; Jocelyn Jayme; Kieran G O'Connor; Colleen Christmas; Jordan D Tobin; Kerry J Stewart; Ernest Cottrell; Carol St Clair; Katharine M Pabst; S Mitchell Harman Journal: JAMA Date: 2002-11-13 Impact factor: 56.272
Authors: G Amato; G Mazziotti; C Di Somma; E Lalli; G De Felice; M Conte; M Rotondi; M Pietrosante; G Lombardi; A Bellastella; C Carella; A Colao Journal: J Clin Endocrinol Metab Date: 2000-10 Impact factor: 5.958
Authors: S Bhasin; L Woodhouse; R Casaburi; A B Singh; D Bhasin; N Berman; X Chen; K E Yarasheski; L Magliano; C Dzekov; J Dzekov; R Bross; J Phillips; I Sinha-Hikim; R Shen; T W Storer Journal: Am J Physiol Endocrinol Metab Date: 2001-12 Impact factor: 4.310
Authors: Fred R Sattler; Carmen Castaneda-Sceppa; Ellen F Binder; E Todd Schroeder; Ying Wang; Shalender Bhasin; Miwa Kawakubo; Yolanda Stewart; Kevin E Yarasheski; Jagadish Ulloor; Patrick Colletti; Ronenn Roubenoff; Stanley P Azen Journal: J Clin Endocrinol Metab Date: 2009-03-17 Impact factor: 5.958
Authors: G G Verde; I Santi; P Chiodini; R Cozzi; D Dallabonzana; G Oppizzi; A Liuzzi Journal: J Clin Endocrinol Metab Date: 1986-12 Impact factor: 5.958
Authors: Dominique Dardevet; Isabelle Savary-Auzeloux; Didier Remond; Laurent Mosoni; Emanuele Marzetti; Thomas W Buford; Roberto Bernabei; Isabelle J Dionne; Thomas W Buford; Emanuele Marzetti; Todd M Manini; Bjoern Buehring; Elizabeth Kirchner; Leonard Calabrese; Todd M Manini; Brian C Clark; Helder M Fonseca; Osvaldo Delbono; Jackson R Taylor; Mylène Aubertin-Leheudre; Sébastien Barbat-Artigas; Charlotte H Pion; Lars-Eric Thornell; Thomas Gustafsson; Tommy Cederholm; Brun Ulfhake Journal: J Appl Physiol (1985) Date: 2012-08-15
Authors: Grace Huang; Guilherme V Rocha; Karol M Pencina; Karen Cox; Venkatesh Krishnan; Kim Henriksen; Peter Mitchell; Sean E Sissons; Zhuoying Li; Anders F Nedergaard; Morten A Karsdal; Shu Sun; Thomas W Storer; Shehzad Basaria; Shalender Bhasin Journal: J Clin Endocrinol Metab Date: 2019-05-23 Impact factor: 5.958
Authors: Mette J Nielsen; Anders F Nedergaard; Shu Sun; Sanne S Veidal; Lise Larsen; Qinlong Zheng; Charlotte Suetta; Kim Henriksen; Claus Christiansen; Morten A Karsdal; Diana J Leeming Journal: Am J Transl Res Date: 2013-04-19 Impact factor: 4.060
Authors: Sarah D Berry; Vasan S Ramachandran; Peggy M Cawthon; Philimon Gona; Robert R McLean; L Adrienne Cupples; Douglas P Kiel Journal: J Frailty Aging Date: 2013
Authors: Fabian Chen; Raymond Lam; David Shaywitz; Ronald C Hendrickson; Gregory J Opiteck; Dana Wishengrad; Andy Liaw; Qinghua Song; Adrian J Stewart; Corinne E Cummings; Chan Beals; Kevin E Yarasheski; Alise Reicin; Marcella Ruddy; Xuguang Hu; Nathan A Yates; Joseph Menetski; Gary A Herman Journal: J Cachexia Sarcopenia Muscle Date: 2011-02-26 Impact factor: 12.910
Authors: Matteo Cesari; Roger A Fielding; Marco Pahor; Bret Goodpaster; Marc Hellerstein; Gabor A van Kan; Stefan D Anker; Seward Rutkove; J Willem Vrijbloed; Maria Isaac; Yves Rolland; Christine M'rini; Mylène Aubertin-Leheudre; Jesse M Cedarbaum; Mauro Zamboni; Cornell C Sieber; Didier Laurent; William J Evans; Ronenn Roubenoff; John E Morley; Bruno Vellas Journal: J Cachexia Sarcopenia Muscle Date: 2012-08-03 Impact factor: 12.910